阅读说明：本技术 Pim1小分子抑制剂在制备防治强直性脊柱炎产品中的应用 (Application of Pim1 small-molecule inhibitor in preparation of product for preventing and treating ankylosing spondylitis ) 是由 沈慧勇 吴燕峰 苏泽鹏 谢中瑜 李进腾 于 2021-07-26 设计创作，主要内容包括：本发明属于医药生物技术领域,具体涉及Pim1小分子抑制剂在制备防治强直性脊柱炎产品中的应用,本发明使用Pim1的特异性小分子抑制剂AZD1208,通过体内及体外实验证明了Pim1在Th17分化中的重要作用,证实了Pim1可作为阻断Th17分化与IL-17A分泌的靶点,并验证了用AZD1208治疗AS的安全性、有效性、可行性。与IL-17A单克隆抗体相比,pim1通过阻断Th17分化治疗AS,在机制上处于IL-17A单克隆抗体作用的上游,因此本发明能为治疗AS提供了新的靶点以及新的途径,为AS患者尤其是IL-17A单克隆抗体治疗效果不佳的患者提供新的选择。(The invention belongs to the technical field of medical biology, and particularly relates to an application of a Pim1 small-molecule inhibitor in preparation of a product for preventing and treating ankylosing spondylitis, wherein a specific small-molecule inhibitor AZD1208 of Pim1 is used, in-vivo and in-vitro experiments prove that Pim1 plays an important role in Th17 differentiation, so that Pim1 can be used AS a target for blocking Th17 differentiation and IL-17A secretion, and the safety, effectiveness and feasibility of using AZD1208 to treat AS are verified. Compared with the IL-17A monoclonal antibody, the pim1 treats the AS by blocking Th17 differentiation, and is positioned upstream of the effect of the IL-17A monoclonal antibody in mechanism, so the invention can provide a new target and a new way for treating the AS and provides a new choice for AS patients, particularly patients with poor treatment effect of the IL-17A monoclonal antibody.)

The application of the Pim1 small-molecule inhibitor in preparing a product for preventing and treating ankylosing spondylitis is characterized in that the Pim1 small-molecule inhibitor is a biological functional molecule with the molecular weight of less than 1000 Da.

2. The use as claimed in claim 1 wherein the small molecule inhibitor of Pim1 includes but is not limited to the specific inhibitor AZD1208 of Pim 1.

3. The use according to claim 1, wherein the prevention and treatment of ankylosing spondylitis is the inhibition of Th17 differentiation.

4. The use according to claim 1, wherein the ankylosing spondylitis prevention and treatment product comprises but is not limited to a drug for ankylosing spondylitis and a health-care functional food for ankylosing spondylitis.

5. A medicine for preventing and treating ankylosing spondylitis is characterized in that a Pim1 small-molecule inhibitor is used as a main active ingredient.

6. The medicament for preventing and treating ankylosing spondylitis according to claim 5, further comprising a pharmaceutically acceptable carrier and/or adjuvant.

7. The medicament for preventing and treating ankylosing spondylitis according to claim 5, wherein the dosage form of the medicament includes, but is not limited to, injection, oral liquid, tablet, granule, capsule, pill.

8. A health-care functional food for preventing and treating ankylosing spondylitis is characterized in that a Pim1 small-molecule inhibitor is used as a main active ingredient.

9. The health-care functional food for preventing and treating ankylosing spondylitis of claim 8, further comprising a food-acceptable carrier and/or an auxiliary material.

10. The health-care functional food for preventing and treating ankylosing spondylitis as claimed in claim 8, wherein the form of the food includes, but is not limited to, decoctions, beverages, candies, oral liquids, capsules, tablets and powders.

Technical Field

The invention belongs to the technical field of medical biology, and particularly relates to an application of a Pim1 small-molecule inhibitor in preparation of a product for preventing and treating ankylosing spondylitis.

Background

Ankylosing Spondylitis (AS) is a common autoimmune disease. The incidence of AS is high, about 0.2-0.54% in China, and the ratio of male to female is 2-3:1, which is better for young and strong people. The AS is characterized by chronic progressive inflammation and pathological osteogenesis which affect the central axial bone joint, the clinical manifestations are inflammatory low back pain and central axial bone joint ankylosis deformity, in the chronic progress of the disease, the labor capacity of the patient is gradually reduced and even lost, and the life quality is seriously influenced. Because AS can not be completely cured, the method brings heavy economic burden to countries and individuals.

At present, the pathogenesis of AS is not completely elucidated, but more and more researches in recent years show that Th17 cells and IL-17A secreted by the Th17 cells play an important role in promoting the generation and development of AS. Th17 is caused by peripheral bloodT cells develop, the differentiation level of the T cells is in positive correlation with the activity of AS diseases, and the secreted IL-17A participates in a plurality of processes of AS pathophysiology. IL-17A plays a promoting role in the early stage of AS functioning AS the stop inflammation to mediate inflammation, and IL-17A also serves AS an amplifier of the stop inflammation to induce local interstitial cells to generate inflammatory factors to participate in the reaction process of inflammation. In bone tissue, IL-17A inhibits osteoblasts and chondrocytes from producing a matrix, induces osteoblasts to express RANKL, activates osteoclasts, and causes bone destruction. In addition, IL-17A plays a role in sensitizing the symptoms of low back pain of AS patients, and IL-17A enables the patients to be more sensitive to inflammatory stimulation by reducing the stimulation threshold of pain receptors, so that the patients feel stronger pain.

At present, the drugs for clinically treating AS mainly include nonsteroidal anti-inflammatory drugs (NSAIDs), Tumor Necrosis Factor Inhibitors (TNFi), disease-relieving antirheumatic drugs (DMARDs), and the like. The NSAIDs can improve symptoms of low back pain, morning stiffness and joint pain of partial patients, but the treatment response of partial patients to the NSAIDs is poor and the side effect is obvious after long-term administration. DMARDs are mainly used to treat peripheral arthritis, but have poor therapeutic effect on spine disease-predominant AS. TNFa can block the activity of TNF and inhibit the progress of pathological changes, and is suitable for patients with symptoms outside the relevant segment and without the treatment effect of NSAIDs. Based on the important role and clinical evaluation of IL-17A in the generation and development of AS, the IL-17A monoclonal antibody secukinumab is approved for treating AS in 2020 in China. Although Secukinumab shows a certain therapeutic effect clinically, the effect is still poor for some AS patients. In addition, Secukinumab is expensive, and its use causes a large economic burden on most patients, and thus its universality is not high. Therefore, there is a need to explore new AS therapeutic targets and to find small molecule inhibitors that specifically inhibit the target in order to bring safe and effective new methods for the clinical treatment of AS.

Disclosure of Invention

In order to overcome the defects of the prior art, in vivo and in vitro experiments show that the specific small molecule inhibitors of Pim1 such as AZD1208 and the like can effectively prevent and treat the ankylosing spondylitis by taking Pim1 as a new target, and provide a new target and a new way for preventing and treating the ankylosing spondylitis.

In order to achieve the purpose, the invention adopts the technical scheme that:

the invention aims to provide application of a Pim1 small-molecule inhibitor in preparation of a product for preventing and treating ankylosing spondylitis, wherein the Pim1 small-molecule inhibitor is a biological functional molecule with the molecular weight of less than 1000 Da.

Preferably, the Pim1 small molecule inhibitor includes, but is not limited to, the Pim1 specific inhibitor AZD 1208.

The molecular formula of AZD1208 is C₂₁H₂₁N₃O₂S, molecular weight 379.48, structure shown below:

th17 and IL-17A secreted by the same play an important role in the generation and development of AS, and currently, monoclonal antibodies antagonizing IL-17A are clinically used for treating AS, but the treatment effect on partial patients is still poor.

Th17 is derived fromCD4+ T cells, the differentiation of which includes the steps of activation, proliferation and differentiation, are involved in a plurality of Ca2+ related pathways at a molecular level and the phosphorylation of a plurality of proteins, and Th17 and IL-17A secreted by the Th17 play an important role in the generation and development of AS. Pim1 is a phosphorylation kinase in cells, can bind and phosphorylate proteins, can regulate the Ca2+ pathway in cells, has anti-apoptosis and proliferation promoting effects, and therefore, may be a potential target for regulating Th17 differentiation.

Therefore, the invention starts from the source of IL-17A, explores a target point for inhibiting Th17 differentiation, blocks IL-17A secretion, starts with small molecular compounds, and explores safe, effective and highly universal drugs for treating AS. The invention takes Pim1 AS a new AS treatment target, finds that a specific small molecule inhibitor AZD1208 using Pim1 can inhibit the differentiation of CD4+ T cells to Th17, blocks the secretion of IL-17A at the source, has better curative effect on AS, shows better anti-inflammatory effect in vivo and in vitro experiments, and also shows the characteristic of low toxicity. The small-molecule Pim1 inhibitor is used for effectively preventing and treating AS by taking Pim1 AS a target.

Preferably, the prevention and treatment of ankylosing spondylitis is inhibition of differentiation of Th 17.

Preferably, the product for preventing and treating ankylosing spondylitis includes, but is not limited to, medicaments for preventing and treating ankylosing spondylitis and health-care functional foods for preventing and treating ankylosing spondylitis.

The second purpose of the invention is to provide a drug for preventing and treating ankylosing spondylitis, which takes Pim1 small-molecule inhibitor as a main active ingredient.

Preferably, the Pim1 small molecule inhibitor includes, but is not limited to, the Pim1 specific inhibitor AZD 1208.

Preferably, in order to improve the application range of the medicine, the medicine also comprises a pharmaceutically acceptable carrier and/or an auxiliary material. The carrier and/or adjuvant comprises sour agent, toning agent, flavoring agent, sweetening agent, or their combination.

Preferably, the dosage form of the medicament includes, but is not limited to, injection, oral liquid, tablet, granule, capsule, and pill.

The third purpose of the invention is to provide a health-care functional food for preventing and treating ankylosing spondylitis, which takes Pim1 small-molecule inhibitor as a main active ingredient.

Preferably, the Pim1 small molecule inhibitor includes, but is not limited to, the Pim1 specific inhibitor AZD 1208.

Preferably, to increase the applicability of the food product, the food product further comprises a food acceptable carrier and/or auxiliary material. The carrier and/or adjuvant comprises diluent, excipient, filler, binder, humectant, disintegrating agent, absorption enhancer, sweetener, flavoring agent, or their combination.

Preferably, the food product is in the form of, but not limited to, a decoction, a beverage, a candy, an oral liquid, a capsule, a tablet, and a powder.

Compared with the prior art, the invention has the beneficial effects that:

the invention uses a specific small molecule inhibitor AZD1208 of Pim1, proves the important function of Pim1 in Th17 differentiation through in vivo and in vitro experiments, proves that Pim1 can be used AS a target for blocking Th17 differentiation and IL-17A secretion, and verifies the safety, effectiveness and feasibility of using AZD1208 to treat AS. Meanwhile, compared with the IL-17A monoclonal antibody, the pim1 treats the AS by blocking Th17 differentiation, and is positioned upstream of the IL-17A in mechanism, so the invention can provide a new target and a new way for treating the AS and provides a new choice for AS patients, particularly patients with poor treatment effect of the IL-17A monoclonal antibody.

Drawings

FIG. 1 is a flow chart of an experiment of example 1;

FIG. 2 shows Pim1 expression during differentiation of CD4+ T cells to Th 17;

FIG. 3 is a graph of differentiation of CD4+ T cells to Th17 following treatment with AZD1208 inhibitor;

figure 4 is a graph of the toxic effect of AZD1208 on CD4+ T cells;

FIG. 5 shows the arthritis scores of CIA mice treated with the pam 1-specific inhibitor AZD1208 after injection;

FIG. 6 shows changes in liver and kidney function indexes of CIA mice treated with the injection of the specific inhibitor AZD1208 of pim 1.

Detailed Description

The following further describes the embodiments of the present invention. It should be noted that the description of the embodiments is provided to help understanding of the present invention, but the present invention is not limited thereto. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.

The experimental procedures in the following examples were carried out by conventional methods unless otherwise specified, and the test materials used in the following examples were commercially available by conventional methods unless otherwise specified.

Example 1 Pim1 Small molecule inhibitor has curative effect on ankylosing spondylitis by inhibiting Th17 differentiation

The experimental flow is shown in fig. 1, and the specific process is as follows:

1. in vitro experiments

(1) Inhibition of Pim1 effect on Th17 differentiation

CD4+ T cells were sorted from human peripheral blood mononuclear cells (from healthy blood donated volunteers) using human CD4 magnetic beads (purchased from America whirlpool, cat # 130-:

adding peripheral blood gently onto Ficoll separating medium at volume ratio of 1:1, centrifuging at 400g rotation speed (acceleration 1, deceleration 0) for 35min, carefully sucking white membrane layer with Pasteur pipette, washing with PBS twice, centrifuging to remove supernatant, suspending cells with 1640 medium containing 10% FBS, counting, and culturing at each 10%⁶2uL of magnetic beads and 8uLbuffer (PBS 100mL + 0.5% BSA (0.5g) +2mM EDTA (0.654 g)) were added to each cell, the pH was adjusted to 7.2 with NaOH, and the mixture was sterilized by filtration, mixed well, and incubated at 4 ℃ for 15 minutes in the dark.Adding an appropriate amount of buffer, centrifuging for 10min at 300g, discarding the supernatant, and mixing with 500. mu.L of buffer/10⁸And resuspending the cells. Placing the separation column on a magnetic frame, moistening with a buffer, injecting cells into the separation column, washing with the buffer for 3 times, taking the separation column off the magnetic frame, adding 1mL of buffer, washing out the cells in the separation column, centrifuging for 5min at 1500 rpm, discarding the supernatant, resuspending with 1mL of 1640 medium containing 10% FBS, counting, and performing 0.6 × 10⁶Cell/well plate.

Under the polarization condition of Th17 (anti-CD 31 ug/mL, anti-CD 281 ug/mL, IL-2330 ng/mL, IL-620 ng/mL and TGF-beta 5ng/mL), CD4+ T cells are induced to differentiate to Th17, and meanwhile, a pim1 specific small molecule inhibitor AZD 120820 uM or an equal volume of DMSO is given to treat the cells, and after 3 days of culture, the proportion of Th17 differentiation is detected by flow cytometry by taking CD4 and IL-17A as markers.

As shown in fig. 2 and fig. 3, it was found that expression of Pim1 was up-regulated during differentiation of CD4+ T cells to Th17, but the proportion of Th17 differentiation was significantly decreased after inhibiting Pim1 activity using AZD 1208;

(2) toxicity of AZD1208 inhibitors on CD4+ T cells

The toxicity of the drug on the cells was detected using CCK-8 enzyme-labeled assay. The specific detection is as follows: to a 96-well plate, 100uL of Th17 polarization-cultured CD4+ T cells (about 5000 cells) were added, and AZD1208 or an equal volume of DMSO was added, respectively, while a cell-free culture solution was added as a blank, and 5 duplicate wells were set for each group. To each well, 10uL of CCK-8 solution was added, incubated for 2 hours, and absorbance was measured at 450nm using a microplate reader. In the detection range, the absorbance at 450nm is approximately proportional to the cell activity.

As shown in figure 4, inhibition of Pim1 using AZD1208 was found to be less toxic to CD4+ T cells.

2. In vivo experiments

(1) Inhibition of the therapeutic effect of Pim1 on CIA

As an arthritis-inducing subject, 6-8-week-old DBA/1 female mice (purchased from Jiangsu Geigo Kangbiotech Co., Ltd.) were used, CFA (Freund's complete adjuvant, 1mg/mL) and type II collagen (2mL/mL) were completely emulsified on ice, transferred into a 1mL syringe, centrifuged, and then 100uL was intradermally injected into the groin of each mouse. After 21 days, the mice were boosted (Freund's incomplete adjuvant IFA + type II collagen) to establish a collagen-induced arthritis model (CIA), and 5 CIA mice per group were divided into an experimental group and a control group. AZD1208 was dissolved in DMSO to make a 60mg/mL solution and diluted with methylcellulose to a 3mg/mL suspension, and the CIA was treated by gavage with AZD1208 (control: equivalent ratio of methylcellulose to DMSO) at a dose of 1 dose per day at 30mg/kg body weight for 21 consecutive doses, with an arthritis score every 3 days.

As shown in fig. 5, after 21 days of continuous administration, AZD1208, a specific small molecule inhibitor of Pim1, was found to significantly reduce the arthritis score in CIA mice.

(2) Toxic effects of AZD1208 inhibitors in vivo

After the above CIA mice were continuously administered for 21 days, the mice were sacrificed by dislocation of the spine on day 21, and peripheral blood indices for detecting liver and kidney functions [ detection of serum aspartate Aminotransferase (AST) by MDH method, detection of alanine Aminotransferase (ALT) by lactate dehydrogenase method, detection of serum creatinine (Scr) by picric acid method, and detection of serum urea nitrogen (BUN) by urease-glutamate dehydrogenase method ] were collected. As shown in figure 6, it was found that inhibition of Pim1 activity in vivo using AZD1208 did not cause severe impairment of hepatic and renal function.

The experiments show that the Pim1 specific small molecule inhibitor AZD1208 can inhibit CD4+ T cells from differentiating to Th17, block the secretion of IL-17A at the source, has a good curative effect on Ankylosing Spondylitis (AS), shows a good anti-inflammatory effect in both in vivo and in vitro experiments, and also shows the characteristic of low toxicity. It can be seen that Pim1 can be a new target for AS therapy.

The embodiments of the present invention have been described in detail, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, and the scope of protection is still within the scope of the invention.